BUSINESS NEWS
Cord Blood America Launches Revolutionary Pricing Plan to Provide Affordable Umbilical Cord Blood Stem Cell Preservation
The plan is simple: No money down and no payment until six months after the child is born.
Article
Progenitor Cell Therapy Inks Manufacturing Deal with Cellerant Therapeutics to Bring Stem Cell Treatment to Market
Progenitor Cell Therapy, LLC (PCT), a leading cell engineering and cell therapy services company, announced today that its cGMP facility in Mountain View, California will serve as the manufacturing site for Cellerant Therapeutics, Inc.’s (Cellerant) premier product.
Article
Saneron CCEL Therapeutics, Inc. And University of Minnesota Sign An Exclusive License For An Umbilical Cord Blood Stem Cell Line
According to the agreement, Saneron CCEL will provide research funding and make milestone payments in return for worldwide exclusive development, marketing, and manufacturing rights to the cell line developed.
Article
CryoLife Announces First Human Implants of BioDisc(TM) Spinal Disc Repair System
CryoLife, Inc., a biomaterials and biosurgical device company, announced today that BioDisc(TM) Spinal Disc Repair System, a nucleus pulposus repair device, was successfullyimplanted in two patients.
Article
Bystander Effect of Introgen’s INGN 241 Increases Cancer-Killing Activity in Breast Cancer Cells
Researchers at Introgen Therapeutics, Inc. and their collaborators at The University ofTexas M. D. Anderson Cancer Center today reported that MDA-7 protein released from cells treated with INGN 241 can kill nearby, untreated breast cancer cells resulting in additional therapeutic effect.
Article
Knock-out US Deal Means Mice Could Roar for Stem Cell
Stem Cell Sciences is to receive £650,000 and “a large number” of genetically-engineered “knock-out” mice as part of a new licensing deal with the US’s Deltagen, the company announced yesterday.
Article
MedImmune, Inc. And VasGene Therapeutics Inc. Announce Collaboration To Develop Monoclonal Antibodies Targeting Cancer
MedImmune, Inc. and VasGene Therapeutics, Inc. announced today that they have entered into a collaborative agreement to develop cancer- focused monoclonal antibodies (MAbs) targeting a novel member of a subfamily of receptor tyrosine kinases, EphB4, as well as its ligand, EphrinB2.
Article
Microbix Biosystems Inc. Announces Update On Vaccine Technology; Ends Talks With Vaccine Manufacturer
Microbix Biosystems Inc announced today that the Company has ceased negotiations with the previously announced vaccine manufacturer currently evaluating Microbix’ yield enhancement technology.
Article
MultiCell Technologies Inc. Forms New Company To Develop Novel Therapies For Diabetes And Other Autoimmune Diseases
Alliance Pharmaceutical Corp. (“Alliance”) and its wholly owned subsidiary, Astral, Inc. (“Astral”) today announced that they have transferred substantially all of the assets of Astral and the business of Astral to Astral Therapeutics, Inc., a newly created entity formed solely for this purpose, and to be re-named MultiCell Immunotherapeutics, Inc. (“MCTI”), as set forth below.
Article
Progenics Reports Positive Results from Phase 1 Clinical Trial of PRO 140, a Novel Monoclonal Antibody That Blocks HIV Entry; Single Dose Coats Immune Cells for Two Months, Potential Long-Acting HIV Therapy
Article
Oxxon Therapeutics Presents Positive Data Evaluating DNA/MVA PrimeBoost Immunotherapy in Metastatic Melanoma Patients
Oxxon’s PrimeBoost immunotherapy delivers multiple melanoma specific epitopes in a priming and boosting regimen.
Article
MARKET REPORTS
Malachite Management has joined forces with established and reputable authors and publishers to bring you the following market reports outlining the very latest in Cell Therapy, Gene Therapy, and Immunotherapeutic approaches to Cancer.
“Cell Therapy – Technologies, Markets, and Companies” is over 400 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the cell therapy industry worldwide.
For more information, including order forms, please see:
Cell Therapy Report Summary
Cell Therapy Sample Chapter
Cell Therapy Table of Contents Vol. 1 Vol. 2
Cell Therapy Order Form
“Gene Therapy – Technologies, Markets, and Companies” is over 500 pages of the basic technologies, clinical applications, market analysis, and company profiles related to the gene therapy industry worldwide.
For more information, including order forms, please see:
Gene Therapy Report Summary
Gene Therapy Table of Contents Vol. 1 Vol. 2
Gene Therapy Order Form
The Immunotherapy Reports cover the most recent developments in the immunotherapeutic approaches to cancer.
A Shift in Cancer Immunotherapy Strategies?
Immunotherapy Strategies Executive Summary
Immunotherapy Strategies Table of Contents
Future Perspectives in Cancer Immunotherapy
Future Perspectives Executive Summary
Future Perspectives Table of Contents
Immunotherapy Reports Order Form